Physician profile
John A Garcia
NPI 1649294554
$3,450.01
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $231 · 2021: $1,159 · 2022: $834 · 2023: $400 · 2024: $63.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,575.00 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $478.92 | 2019-2023 | Farxiga, Breztri |
| Gilead Sciences, INC. | $239.56 | 2019-2022 | |
| Allergan, INC. | $239.51 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.23 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $182.74 | 2020-2021 | |
| Inari Medical, INC. | $180.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $76.47 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.17 | 2022 | |
| Scilex Pharmaceuticals INC. | $48.99 | 2019 | |
| Kaleo, INC. | $37.80 | 2019 | |
| Pfizer INC. | $31.44 | 2023 | |
| Eisai INC. | $28.62 | 2021 | |
| Novo Nordisk INC | $26.89 | 2021 | |
| Amarin Pharma, INC. | $15.10 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13.57 | 2022 | |
| Grifols USA, LLC | $12.89 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.